| 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES |
Active Substance:AMLODIPINE BESILATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:AMLODIPINE MALEATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ARIPIPRAZOLE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ARIPIPRAZOLE HEMIFUMARATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ATORVASTATIN CALCIUM |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ATORVASTATIN CALCIUM TRIHYDRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:CANDESARTAN CILEXETIL |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:CARVEDILOL |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:CLOPIDOGREL HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:CLOPIDOGREL HYDROGEN SULFATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:CELECOXIB |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:DESLORATADINE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:DONEPEZIL HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:DULOXETINE HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ENALAPRIL MALEATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ENALAPRILAT DIHYDRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ESOMEPRAZOLE MAGNESIUM |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ETORICOXIB |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:EZETIMIBE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:INDAPAMIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:IRBESARTAN HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:IVABRADINE HYDROBROMIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:LANSOPRAZOLE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:LEVOCETIRIZINE HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:LINEZOLID |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:LOSARTAN POTASSIUM |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:MARBOFLOXACIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:MEMANTINE HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:NORFLOXACIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:OLANZAPINE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:OLMESARTAN MEDOXOMIL |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ORLISTAT |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PANTOPRAZOLE SODIUM SESQIHYDRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PREGABALIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:QUETIAPINE HEMIFUMARATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:RABEPRAZOLE SODIUM |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:RASAGILINE HEMITARTRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:RIVAROXABAN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:RIVASTIGMINE HYDROGEN TARTRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ROPINIROLE HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ROSUVASTATIN CALCIUM |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:SILDENAFIL |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:SILDENAFIL CITRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:SOLIFENACIN SUCCINATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:TADALAFIL |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:TELMISARTAN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:TOLTRAZURIL |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:VALSARTAN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:VENLAFAXINE HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:ZIPRASIDONE HYDROGEN SULFATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:DIOSMIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.3 Salt formation / Purification steps: salt formation
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling, sieving
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:VILDAGLIPTIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PALIPERIDONE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:VARDENAFIL HYDROCHLORIDE TRIHYDRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:TULATHROMYCIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:SILODOSIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:IVABRADINE HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PERINDOPRIL TERT-BUTYLAMINE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PITAVASTATIN CALCIUM |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PRASUGREL |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:SITAGLIPTIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:THIETHYLPERAZINE DIMALATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PERINDOPRIL ARGININE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.3 Salt formation / Purification steps: crystallisation
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: drying
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:DABIGATRAN ETEXILATE MESILATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.3 Salt formation / Purification steps: crystallisation
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: drying, milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:TICAGRELOR |
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:EDOXABAN TOSYLATE MONOHYDRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.3 Salt formation / Purification steps: salt formation
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: drying, milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:APIXABAN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.3 Salt formation / Purification steps: crystallization
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: drying, milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:APREMILAST |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.3 Salt formation / Purification steps: crystallisation
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: drying, sieving
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:LINAGLIPTIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.3 Salt formation / Purification steps: crystallisation
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: drying, milling
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|